Get all your news in one place.
100's of premium titles.
One app.
Start reading
Euronews
Euronews
Marta Iraola Iribarren

Eli Lilly invests in AI-designed drugs in new deal with Insilico Medicine worth up to €2.39bn

Eli Lilly and Insilico Medicine have struck a new deal on AI-driven drug discovery, the companies announced on Sunday.

Under the agreement, worth up to $2.75 ‌billion (€2.39 billion), the American firm Eli Lilly will use Insilico’s artificial intelligence (AI) platform to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.